 Mary Demoruelle
Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 68 | 2026 | 1170 | 11.050 |
Why?
| | Anti-Citrullinated Protein Antibodies | 20 | 2026 | 127 | 5.270 |
Why?
| | Autoantibodies | 35 | 2025 | 1505 | 4.300 |
Why?
| | Lung Diseases, Interstitial | 16 | 2025 | 660 | 3.520 |
Why?
| | Connective Tissue Diseases | 5 | 2024 | 84 | 2.770 |
Why?
| | Sputum | 6 | 2025 | 308 | 2.440 |
Why?
| | Immunoglobulin A | 10 | 2023 | 214 | 2.230 |
Why?
| | Extracellular Traps | 4 | 2023 | 51 | 2.080 |
Why?
| | Peptides, Cyclic | 14 | 2026 | 275 | 2.080 |
Why?
| | Idiopathic Pulmonary Fibrosis | 6 | 2023 | 691 | 1.830 |
Why?
| | Immunity, Mucosal | 4 | 2020 | 98 | 1.650 |
Why?
| | Autoimmunity | 11 | 2025 | 930 | 1.530 |
Why?
| | Antirheumatic Agents | 3 | 2026 | 304 | 1.250 |
Why?
| | Rheumatoid Factor | 12 | 2025 | 178 | 0.920 |
Why?
| | Hydroxychloroquine | 1 | 2026 | 63 | 0.900 |
Why?
| | Pulmonary Fibrosis | 2 | 2025 | 393 | 0.840 |
Why?
| | Infertility, Female | 1 | 2024 | 111 | 0.800 |
Why?
| | Fertility | 1 | 2024 | 166 | 0.780 |
Why?
| | Antiphospholipid Syndrome | 1 | 2023 | 37 | 0.770 |
Why?
| | Citrullination | 3 | 2020 | 12 | 0.750 |
Why?
| | Bronchial Diseases | 2 | 2013 | 38 | 0.740 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 475 | 0.730 |
Why?
| | Inflammation | 6 | 2025 | 2870 | 0.680 |
Why?
| | Citrulline | 3 | 2020 | 46 | 0.660 |
Why?
| | Humans | 76 | 2026 | 144671 | 0.650 |
Why?
| | Microbiota | 3 | 2021 | 782 | 0.630 |
Why?
| | Lupus Erythematosus, Systemic | 3 | 2022 | 238 | 0.590 |
Why?
| | Pregnancy Complications | 1 | 2024 | 586 | 0.570 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2023 | 835 | 0.550 |
Why?
| | Autoantigens | 4 | 2022 | 425 | 0.540 |
Why?
| | Pedigree | 2 | 2020 | 515 | 0.500 |
Why?
| | Lung | 8 | 2023 | 4089 | 0.500 |
Why?
| | Middle Aged | 36 | 2026 | 35971 | 0.490 |
Why?
| | Lung Diseases | 2 | 2013 | 781 | 0.460 |
Why?
| | Aged | 24 | 2026 | 25955 | 0.460 |
Why?
| | Female | 43 | 2026 | 78304 | 0.420 |
Why?
| | Disease Progression | 10 | 2025 | 2847 | 0.420 |
Why?
| | Pneumonia | 1 | 2020 | 629 | 0.400 |
Why?
| | Male | 40 | 2026 | 72431 | 0.390 |
Why?
| | Neutrophil Activation | 2 | 2025 | 84 | 0.380 |
Why?
| | Asymptomatic Diseases | 1 | 2012 | 103 | 0.360 |
Why?
| | Risk Factors | 17 | 2025 | 10796 | 0.350 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 113 | 0.350 |
Why?
| | Arthritis | 1 | 2012 | 96 | 0.350 |
Why?
| | Respiration Disorders | 2 | 2022 | 78 | 0.340 |
Why?
| | Adult | 28 | 2026 | 40489 | 0.340 |
Why?
| | Protein-Arginine Deiminases | 3 | 2021 | 16 | 0.340 |
Why?
| | Mucin-5B | 2 | 2025 | 234 | 0.330 |
Why?
| | Case-Control Studies | 10 | 2025 | 3603 | 0.330 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2017 | 141 | 0.330 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 465 | 0.310 |
Why?
| | B-Lymphocytes | 2 | 2025 | 875 | 0.290 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 324 | 0.290 |
Why?
| | Respiratory Function Tests | 3 | 2025 | 541 | 0.290 |
Why?
| | Biomarkers | 8 | 2025 | 4261 | 0.290 |
Why?
| | Neutrophils | 3 | 2025 | 1118 | 0.280 |
Why?
| | Prospective Studies | 13 | 2025 | 7994 | 0.270 |
Why?
| | Histones | 3 | 2021 | 663 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 4 | 2025 | 2754 | 0.250 |
Why?
| | Epitopes | 5 | 2023 | 479 | 0.240 |
Why?
| | Receptors, Formyl Peptide | 1 | 2025 | 17 | 0.230 |
Why?
| | Intestines | 2 | 2021 | 357 | 0.220 |
Why?
| | Chlamydia trachomatis | 1 | 2025 | 49 | 0.210 |
Why?
| | Early Diagnosis | 4 | 2025 | 249 | 0.210 |
Why?
| | Chlamydia Infections | 1 | 2025 | 79 | 0.200 |
Why?
| | Adenylate Kinase | 1 | 2023 | 26 | 0.200 |
Why?
| | Genetic Predisposition to Disease | 3 | 2022 | 2350 | 0.200 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2024 | 130 | 0.200 |
Why?
| | Antibody Formation | 3 | 2022 | 291 | 0.200 |
Why?
| | Scleroderma, Systemic | 1 | 2024 | 123 | 0.200 |
Why?
| | HLA-DR Antigens | 1 | 2024 | 220 | 0.190 |
Why?
| | Incidence | 5 | 2021 | 2892 | 0.180 |
Why?
| | Immunosuppressive Agents | 2 | 2024 | 834 | 0.180 |
Why?
| | Plant Extracts | 1 | 2023 | 188 | 0.170 |
Why?
| | Double-Blind Method | 1 | 2026 | 2033 | 0.170 |
Why?
| | Dysbiosis | 2 | 2020 | 187 | 0.170 |
Why?
| | Hydrolases | 1 | 2021 | 55 | 0.160 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2021 | 96 | 0.160 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 101 | 0.160 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 8 | 0.160 |
Why?
| | Chemokine CXCL16 | 1 | 2020 | 4 | 0.160 |
Why?
| | Vimentin | 1 | 2020 | 54 | 0.160 |
Why?
| | Milk Proteins | 1 | 2020 | 33 | 0.160 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 205 | 0.150 |
Why?
| | Muramidase | 1 | 2020 | 66 | 0.150 |
Why?
| | Malondialdehyde | 1 | 2019 | 30 | 0.150 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 193 | 0.150 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2020 | 87 | 0.150 |
Why?
| | Acetaldehyde | 1 | 2019 | 17 | 0.150 |
Why?
| | Bacteriophages | 1 | 2021 | 111 | 0.150 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 146 | 0.150 |
Why?
| | Mammary Glands, Animal | 1 | 2020 | 128 | 0.150 |
Why?
| | Nuclear Family | 1 | 2019 | 50 | 0.150 |
Why?
| | Family Characteristics | 1 | 2020 | 198 | 0.140 |
Why?
| | Immunoglobulin G | 5 | 2023 | 886 | 0.140 |
Why?
| | Leukocytes, Mononuclear | 2 | 2024 | 572 | 0.140 |
Why?
| | Lactation | 1 | 2020 | 192 | 0.140 |
Why?
| | Arthritis, Experimental | 1 | 2020 | 141 | 0.140 |
Why?
| | Occupational Exposure | 1 | 2022 | 355 | 0.140 |
Why?
| | Monocytes | 1 | 2020 | 536 | 0.130 |
Why?
| | Mucous Membrane | 1 | 2018 | 128 | 0.130 |
Why?
| | T-Lymphocytes | 1 | 2025 | 1984 | 0.130 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2016 | 48 | 0.120 |
Why?
| | Prevalence | 2 | 2022 | 2839 | 0.120 |
Why?
| | Plasma Cells | 1 | 2016 | 79 | 0.120 |
Why?
| | Complement System Proteins | 1 | 2019 | 314 | 0.120 |
Why?
| | Peptides | 1 | 2021 | 989 | 0.110 |
Why?
| | Molecular Mimicry | 1 | 2014 | 37 | 0.110 |
Why?
| | Immunoglobulin M | 3 | 2022 | 281 | 0.100 |
Why?
| | Mitochondria | 1 | 2021 | 984 | 0.100 |
Why?
| | Animals | 5 | 2023 | 37948 | 0.100 |
Why?
| | Mouth Mucosa | 1 | 2014 | 87 | 0.100 |
Why?
| | Cross-Sectional Studies | 5 | 2023 | 5870 | 0.100 |
Why?
| | Pneumocystis carinii | 1 | 2013 | 12 | 0.100 |
Why?
| | Mice | 4 | 2023 | 18261 | 0.100 |
Why?
| | Young Adult | 3 | 2021 | 14122 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2013 | 305 | 0.090 |
Why?
| | Arthrography | 1 | 2011 | 18 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1148 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1995 | 0.090 |
Why?
| | Population Surveillance | 1 | 2015 | 484 | 0.090 |
Why?
| | Remission Induction | 1 | 2012 | 309 | 0.090 |
Why?
| | Prognosis | 2 | 2021 | 4312 | 0.090 |
Why?
| | Mass Screening | 1 | 2020 | 1348 | 0.090 |
Why?
| | Pregnancy | 1 | 2024 | 7122 | 0.090 |
Why?
| | Age Factors | 1 | 2019 | 3329 | 0.090 |
Why?
| | Blood Pressure | 1 | 2017 | 1766 | 0.080 |
Why?
| | Joints | 1 | 2011 | 107 | 0.080 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1322 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2022 | 11735 | 0.080 |
Why?
| | Time-to-Treatment | 1 | 2012 | 242 | 0.080 |
Why?
| | Time Factors | 3 | 2020 | 7140 | 0.080 |
Why?
| | Air Pollution | 1 | 2013 | 318 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2021 | 342 | 0.070 |
Why?
| | Vital Capacity | 2 | 2022 | 290 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1501 | 0.070 |
Why?
| | Organ Specificity | 2 | 2019 | 311 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1207 | 0.060 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2025 | 40 | 0.060 |
Why?
| | Cohort Studies | 3 | 2022 | 5957 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2021 | 1537 | 0.050 |
Why?
| | Switzerland | 1 | 2025 | 46 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2922 | 0.050 |
Why?
| | Family | 2 | 2021 | 685 | 0.050 |
Why?
| | Smoking | 2 | 2024 | 1467 | 0.050 |
Why?
| | Receptors, CXCR5 | 1 | 2024 | 27 | 0.050 |
Why?
| | Telomere Shortening | 1 | 2024 | 19 | 0.050 |
Why?
| | Prevotella | 1 | 2023 | 26 | 0.050 |
Why?
| | Azathioprine | 1 | 2022 | 44 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 35 | 0.050 |
Why?
| | Rituximab | 1 | 2022 | 211 | 0.040 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2021 | 35 | 0.040 |
Why?
| | Genetic Markers | 1 | 2022 | 332 | 0.040 |
Why?
| | Arthralgia | 1 | 2021 | 61 | 0.040 |
Why?
| | Cytokines | 2 | 2020 | 2045 | 0.040 |
Why?
| | Vitamins | 1 | 2022 | 176 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 176 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 669 | 0.040 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 83 | 0.040 |
Why?
| | Telomere | 1 | 2024 | 290 | 0.040 |
Why?
| | Synovial Fluid | 1 | 2020 | 68 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2020 | 66 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2024 | 1154 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2021 | 269 | 0.040 |
Why?
| | Prolactin | 1 | 2020 | 87 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2020 | 127 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2020 | 364 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2020 | 178 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 318 | 0.040 |
Why?
| | Endotoxins | 1 | 2020 | 218 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2021 | 390 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2025 | 1129 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4558 | 0.040 |
Why?
| | Methotrexate | 1 | 2020 | 231 | 0.040 |
Why?
| | Arginine | 1 | 2020 | 238 | 0.040 |
Why?
| | Vitamin D | 1 | 2022 | 400 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 601 | 0.030 |
Why?
| | Gene Frequency | 1 | 2019 | 481 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 503 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2022 | 672 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 480 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 466 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 496 | 0.030 |
Why?
| | Environment | 1 | 2019 | 306 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5414 | 0.030 |
Why?
| | Genes, Immunoglobulin Light Chain | 1 | 2016 | 4 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 10 | 0.030 |
Why?
| | Phosphofructokinase-2 | 1 | 2016 | 16 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2021 | 770 | 0.030 |
Why?
| | Phylogeny | 1 | 2021 | 1024 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 68 | 0.030 |
Why?
| | Complement Activation | 1 | 2019 | 409 | 0.030 |
Why?
| | Protective Factors | 1 | 2016 | 99 | 0.030 |
Why?
| | Alleles | 1 | 2019 | 886 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2020 | 733 | 0.030 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2015 | 78 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 100 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2016 | 438 | 0.030 |
Why?
| | Proteome | 1 | 2020 | 515 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1505 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1476 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1076 | 0.030 |
Why?
| | Forced Expiratory Volume | 1 | 2015 | 448 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1036 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1370 | 0.030 |
Why?
| | Immunoglobulins | 1 | 2015 | 160 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2022 | 17149 | 0.030 |
Why?
| | Risk | 1 | 2016 | 911 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 828 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 967 | 0.020 |
Why?
| | Proteomics | 1 | 2020 | 1183 | 0.020 |
Why?
| | Geographic Information Systems | 1 | 2013 | 46 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 552 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2942 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 706 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2020 | 4110 | 0.020 |
Why?
| | Signal Transduction | 1 | 2025 | 5185 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2016 | 575 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2020 | 2815 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2137 | 0.020 |
Why?
| | United States | 2 | 2022 | 16018 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3729 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 2089 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2013 | 420 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4081 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 2419 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2013 | 374 | 0.020 |
Why?
| | Erythrocytes | 1 | 2016 | 750 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 337 | 0.020 |
Why?
| | Exercise | 1 | 2021 | 2183 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2591 | 0.020 |
Why?
| | Adolescent | 1 | 2021 | 22409 | 0.010 |
Why?
|
|
Demoruelle's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|